A hepatitis C-vírus-fertőzés szűrése, diagnosztikája, antivirális terápiája, kezelés utáni gondozása. Magyar konszenzusajánlás. Érvényes: 2017. szeptember 22-től

B. Hunyady, Zsuzsanna Gerlei, Judit Gervain, Gábor Horváth, G. Lengyel, A. Pár, Zoltán Péter, László Rókusz, Ferenc Schneider, F. Szalay, István Tornai, Klára Werling, Mihály Makara

Research output: Article

2 Citations (Scopus)

Abstract

The treatment of hepatitis C is based on a national consensus guideline updated six-monthly according to local availability and affordability of approved therapies through a transparent allocation system in Hungary. This updated guideline incorporates some special new aspects, including recommendations for screening, diagnostics, use and allocation of novel direct acting antiviral agents. The indication of therapy in patients with no contraindication is based on the demonstration of viral replication with consequent inflammation and/or fibrosis in the liver. Non-invasive methods (elastographies and biochemical methods) are preferred for liver fibrosis staging. The budget allocated for these patients is limited. Interferon-based or interferon-free therapies are available for the treatment. Due to their limited success rate as well as to their (sometimes severe) side-effects, the mandatory use of interferon-based therapies as first line treatment can not be accepted from the professional point of view. However, they can be used as optional therapy in treatment-naïve patients with mild disease. As of interferon-free therapies, priority is given to those with urgent need based on a pre-defined scoring system reflecting mainly the stage of the liver disease, but considering also additional factors, i.e., hepatic decompensation, other complications, activity and progression of liver disease, risk of transmission and other special issues. Approved treatments are restricted to the most cost-effective combinations based on the cost per sustained virological response value in different patient categories with consensus amongst treating physicians, the National Health Insurance Fund of Hungary and patients' organizations. Interferon-free treatments and shorter therapy durations are preferred. Orv Hetil. 2018; 159(Suppl 1): 3-23.

Original languageHungarian
Pages (from-to)3-23
Number of pages21
JournalOrvosi hetilap
Volume159
DOIs
Publication statusPublished - febr. 1 2018

Fingerprint

Hungary
Hepacivirus
Liver Diseases
Guidelines
Interferons
Therapeutics
Liver Cirrhosis
Costs and Cost Analysis
National Health Programs
Budgets
Hepatitis C
Antiviral Agents

Keywords

  • direct acting antiviral drug
  • direkt ható antivirális szer
  • genotype
  • genotípus
  • hepatitis C virus
  • hepatitis C-vírus
  • hepatocellular carcinoma
  • interferon
  • liver cirrhosis
  • májrák
  • májzsugor
  • polimerázgátló
  • polymerase inhibitor
  • protease inhibitor
  • proteázgátló
  • replication complex inhibitor
  • replikációskomplex-gátló
  • viral hepatitis
  • vírushepatitis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A hepatitis C-vírus-fertőzés szűrése, diagnosztikája, antivirális terápiája, kezelés utáni gondozása. Magyar konszenzusajánlás. Érvényes : 2017. szeptember 22-től. / Hunyady, B.; Gerlei, Zsuzsanna; Gervain, Judit; Horváth, Gábor; Lengyel, G.; Pár, A.; Péter, Zoltán; Rókusz, László; Schneider, Ferenc; Szalay, F.; Tornai, István; Werling, Klára; Makara, Mihály.

In: Orvosi hetilap, Vol. 159, 01.02.2018, p. 3-23.

Research output: Article

Hunyady, B. ; Gerlei, Zsuzsanna ; Gervain, Judit ; Horváth, Gábor ; Lengyel, G. ; Pár, A. ; Péter, Zoltán ; Rókusz, László ; Schneider, Ferenc ; Szalay, F. ; Tornai, István ; Werling, Klára ; Makara, Mihály. / A hepatitis C-vírus-fertőzés szűrése, diagnosztikája, antivirális terápiája, kezelés utáni gondozása. Magyar konszenzusajánlás. Érvényes : 2017. szeptember 22-től. In: Orvosi hetilap. 2018 ; Vol. 159. pp. 3-23.
@article{48433e3b73914285a6d6afc72c951d90,
title = "A hepatitis C-v{\'i}rus-fertőz{\'e}s szűr{\'e}se, diagnosztik{\'a}ja, antivir{\'a}lis ter{\'a}pi{\'a}ja, kezel{\'e}s ut{\'a}ni gondoz{\'a}sa. Magyar konszenzusaj{\'a}nl{\'a}s. {\'E}rv{\'e}nyes: 2017. szeptember 22-től",
abstract = "The treatment of hepatitis C is based on a national consensus guideline updated six-monthly according to local availability and affordability of approved therapies through a transparent allocation system in Hungary. This updated guideline incorporates some special new aspects, including recommendations for screening, diagnostics, use and allocation of novel direct acting antiviral agents. The indication of therapy in patients with no contraindication is based on the demonstration of viral replication with consequent inflammation and/or fibrosis in the liver. Non-invasive methods (elastographies and biochemical methods) are preferred for liver fibrosis staging. The budget allocated for these patients is limited. Interferon-based or interferon-free therapies are available for the treatment. Due to their limited success rate as well as to their (sometimes severe) side-effects, the mandatory use of interferon-based therapies as first line treatment can not be accepted from the professional point of view. However, they can be used as optional therapy in treatment-na{\"i}ve patients with mild disease. As of interferon-free therapies, priority is given to those with urgent need based on a pre-defined scoring system reflecting mainly the stage of the liver disease, but considering also additional factors, i.e., hepatic decompensation, other complications, activity and progression of liver disease, risk of transmission and other special issues. Approved treatments are restricted to the most cost-effective combinations based on the cost per sustained virological response value in different patient categories with consensus amongst treating physicians, the National Health Insurance Fund of Hungary and patients' organizations. Interferon-free treatments and shorter therapy durations are preferred. Orv Hetil. 2018; 159(Suppl 1): 3-23.",
keywords = "direct acting antiviral drug, direkt hat{\'o} antivir{\'a}lis szer, genotype, genot{\'i}pus, hepatitis C virus, hepatitis C-v{\'i}rus, hepatocellular carcinoma, interferon, liver cirrhosis, m{\'a}jr{\'a}k, m{\'a}jzsugor, polimer{\'a}zg{\'a}tl{\'o}, polymerase inhibitor, protease inhibitor, prote{\'a}zg{\'a}tl{\'o}, replication complex inhibitor, replik{\'a}ci{\'o}skomplex-g{\'a}tl{\'o}, viral hepatitis, v{\'i}rushepatitis",
author = "B. Hunyady and Zsuzsanna Gerlei and Judit Gervain and G{\'a}bor Horv{\'a}th and G. Lengyel and A. P{\'a}r and Zolt{\'a}n P{\'e}ter and L{\'a}szl{\'o} R{\'o}kusz and Ferenc Schneider and F. Szalay and Istv{\'a}n Tornai and Kl{\'a}ra Werling and Mih{\'a}ly Makara",
year = "2018",
month = "2",
day = "1",
doi = "10.1556/650.2018.31003",
language = "Hungarian",
volume = "159",
pages = "3--23",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",

}

TY - JOUR

T1 - A hepatitis C-vírus-fertőzés szűrése, diagnosztikája, antivirális terápiája, kezelés utáni gondozása. Magyar konszenzusajánlás. Érvényes

T2 - 2017. szeptember 22-től

AU - Hunyady, B.

AU - Gerlei, Zsuzsanna

AU - Gervain, Judit

AU - Horváth, Gábor

AU - Lengyel, G.

AU - Pár, A.

AU - Péter, Zoltán

AU - Rókusz, László

AU - Schneider, Ferenc

AU - Szalay, F.

AU - Tornai, István

AU - Werling, Klára

AU - Makara, Mihály

PY - 2018/2/1

Y1 - 2018/2/1

N2 - The treatment of hepatitis C is based on a national consensus guideline updated six-monthly according to local availability and affordability of approved therapies through a transparent allocation system in Hungary. This updated guideline incorporates some special new aspects, including recommendations for screening, diagnostics, use and allocation of novel direct acting antiviral agents. The indication of therapy in patients with no contraindication is based on the demonstration of viral replication with consequent inflammation and/or fibrosis in the liver. Non-invasive methods (elastographies and biochemical methods) are preferred for liver fibrosis staging. The budget allocated for these patients is limited. Interferon-based or interferon-free therapies are available for the treatment. Due to their limited success rate as well as to their (sometimes severe) side-effects, the mandatory use of interferon-based therapies as first line treatment can not be accepted from the professional point of view. However, they can be used as optional therapy in treatment-naïve patients with mild disease. As of interferon-free therapies, priority is given to those with urgent need based on a pre-defined scoring system reflecting mainly the stage of the liver disease, but considering also additional factors, i.e., hepatic decompensation, other complications, activity and progression of liver disease, risk of transmission and other special issues. Approved treatments are restricted to the most cost-effective combinations based on the cost per sustained virological response value in different patient categories with consensus amongst treating physicians, the National Health Insurance Fund of Hungary and patients' organizations. Interferon-free treatments and shorter therapy durations are preferred. Orv Hetil. 2018; 159(Suppl 1): 3-23.

AB - The treatment of hepatitis C is based on a national consensus guideline updated six-monthly according to local availability and affordability of approved therapies through a transparent allocation system in Hungary. This updated guideline incorporates some special new aspects, including recommendations for screening, diagnostics, use and allocation of novel direct acting antiviral agents. The indication of therapy in patients with no contraindication is based on the demonstration of viral replication with consequent inflammation and/or fibrosis in the liver. Non-invasive methods (elastographies and biochemical methods) are preferred for liver fibrosis staging. The budget allocated for these patients is limited. Interferon-based or interferon-free therapies are available for the treatment. Due to their limited success rate as well as to their (sometimes severe) side-effects, the mandatory use of interferon-based therapies as first line treatment can not be accepted from the professional point of view. However, they can be used as optional therapy in treatment-naïve patients with mild disease. As of interferon-free therapies, priority is given to those with urgent need based on a pre-defined scoring system reflecting mainly the stage of the liver disease, but considering also additional factors, i.e., hepatic decompensation, other complications, activity and progression of liver disease, risk of transmission and other special issues. Approved treatments are restricted to the most cost-effective combinations based on the cost per sustained virological response value in different patient categories with consensus amongst treating physicians, the National Health Insurance Fund of Hungary and patients' organizations. Interferon-free treatments and shorter therapy durations are preferred. Orv Hetil. 2018; 159(Suppl 1): 3-23.

KW - direct acting antiviral drug

KW - direkt ható antivirális szer

KW - genotype

KW - genotípus

KW - hepatitis C virus

KW - hepatitis C-vírus

KW - hepatocellular carcinoma

KW - interferon

KW - liver cirrhosis

KW - májrák

KW - májzsugor

KW - polimerázgátló

KW - polymerase inhibitor

KW - protease inhibitor

KW - proteázgátló

KW - replication complex inhibitor

KW - replikációskomplex-gátló

KW - viral hepatitis

KW - vírushepatitis

UR - http://www.scopus.com/inward/record.url?scp=85065052026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065052026&partnerID=8YFLogxK

U2 - 10.1556/650.2018.31003

DO - 10.1556/650.2018.31003

M3 - Article

C2 - 29478339

AN - SCOPUS:85065052026

VL - 159

SP - 3

EP - 23

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

ER -